Randomized, double-blind, placebo-controlled phase I dose escalation study of Dan Qi Tong Mai tablet in healthy volunteers

Zhong-ping Gou1†, Wei Zhang2†, Xiu-fang Liang1, Ying Wang1, Ju-hong Mou1, Mei Li1, Ya Zhang3 and Ping Feng1*†

Abstract

Background: This study aims to assess the tolerability and safety of DQTM tablet, which contains a complex mixture of *Salvia miltiorrhiza* salvianolic acids and *Panax notoginseng* saponins.

Methods: A double-blind, randomized, placebo-controlled phase I dose escalation study was conducted in 84 healthy volunteers. In a single ascending dose study, active ingredients were administered in various doses (90, 270, 540, 1080, 1800, 2880, 4320 or 5760 mg) to 60 subjects in cohorts 1–8. In a multiple ascending dose study, active ingredients were administered at doses of 360, 720 or 2160 mg twice daily to 24 subjects in cohorts 9–11 for 14 consecutive days. Safety was evaluated based on clinical symptoms, vital signs, physical examinations, electrocardiography, laboratory tests and adverse events.

Results: No serious adverse events or clinically significant changes in vital signs or electrocardiography were observed. One subject experienced mildly elevated levels of alanine aminotransferase and aspartate transaminase but recovered spontaneously. Five subjects experienced a small increase in the number of daily stools.

Conclusions: DQTM tablet was well tolerated at single doses of up to 5760 mg and twice-daily doses of up to 2160 mg for 14 consecutive days. The most frequent adverse event was an increase in the number of daily stools.

Keywords: *Salvia miltiorrhiza* Bunge, *Panax notoginseng* (Burkill) F.H.Chen, Dan qi Tong Mai tablet, Phase I dose escalation study, Tolerability

Background

Ischemic heart disease is the leading cause of death worldwide [1, 2], and its major type, coronary heart disease, causes an increasing number of deaths each year in China [3]. Approximately 3.5 million people die of cardiovascular disease each year in China, and more than 30% of these deaths are due to ischemic heart disease [4]. Multiple factors contribute to insufficient blood supply to the heart, including critical coronary stenosis, vasospasm, inflammation, microvascular coronary dysfunction, endothelial dysfunction, platelet dysfunction and thrombosis [5]. Several classes of drugs can be used to treat ischemic heart disease: nitroglycerine, statins, angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blocker (ARB), calcium channel blockers, β-receptor antagonists, and anti-platelet agents [6, 7]. Certain patients, such as those with left main coronary artery stenosis >50%, may benefit from revascularization, such as percutaneous coronary intervention (PCI) with drug-eluting stents or coronary artery bypass grafting (CABG) [6, 7]. However, revascularization is unsuitable for many patients, such as those with mild angina and no high-risk findings on stress testing, those with simple coronary artery spasm or those with lesions with <50% stenosis. For these patients, medical therapy based on standard guidelines is recommended [6–8]. Furthermore, resistance to nitrates and aspirin can make treatment of...
ischemic heart disease challenging [9, 10]. Since patients usually require long-term treatment, drug safety remains a significant concern.

Two plants long used in traditional Chinese medicine (TCM) to treat various conditions, including those related to ischemic heart disease, are *Salvia miltiorrhiza Bunge* and *Panax notoginseng (Burkill) F.H.Chen*. They were first described, respectively, in the classics of Chinese Materia Medica *Shen Nong Ben Cao Jin* [11] and *Ben Cao Gang Mu* [12]. They are officially listed in the Chinese Pharmacopeia [13]. *Salvia miltiorrhiza Bunge*, also known as red sage (Danshen), has been used clinically to treat cardiovascular diseases [14–16]. Phenolic acids from this plant, such as salvianolic acids A and B, show anti-platelet and anti-thrombotic activities, which benefit the cardiovascular system [17–27]. *Panax notoginseng* is also known as Sanqi or Tianqi. One of the main active ingredients in *P. notoginseng* is panax notoginseng saponin (PNS), which inhibits inflammation, apoptosis, hypoxia, and coagulation, while promoting angiogenesis [28–32]. PNS contains various chemical components, including noteginsenoside R1, ginsenosides Rg1, Rb1, Re, and Rd. [29, 33–35]. It can be used to treat coronary heart diseases [36–38]. Combination prescriptions such as Fufang Danshen tablet, compound Danshen dripping pill and Danqi tablet are used in the clinic for treatment of coronary heart disease [39–45].

The combination of salvianolic acids and notoginsenosides has better cardioprotective effects than these components on their own [46, 47]. Dan Qi Tong Mai (DQTM) tablet contains *Salvia miltiorrhiza* salvianolic acids and *Panax notoginseng* saponins, and it shows therapeutic potential against coronary heart disease such as angina pectoris, which falls under the blood stagnation syndrome in traditional Chinese medicine theory. While the ratio of the two components has been optimized in preclinical rat studies in which ligation of the front descending coronary artery was used to mimic acute myocardial infarction, the safety and tolerability of the combination of ingredients have not been reported.

The present study aimed to assess the tolerability and safety of DQTM tablet in healthy volunteers. It also explored preliminary analysis of pharmacodynamics.

**Methods**

**Study design**

This study was designed as a randomized, double-blind, placebo-controlled, dose escalation clinical trial. The trial was conducted in the Phase I Trial Unit at West China Hospital, Sichuan University (Chengdu, China) after being approved by the Independent Ethics Committee of West China Hospital [2011 Clinical Trial (TCM) Review (No.1)] and the China Food and Drug Administration. Study procedures were conducted in accordance with the Declaration of Helsinki and the principles of the International Conference on Harmonization Guidelines for Good Clinical Practice. The trial was registered at the World Health Organization International Clinical Trial Registry - Chinese Clinical Trial Registry (http://www.chictr.org.cn; registration number: ChiCTR-TRC-12002276). All eligible individuals were informed about the purpose of the trial, study procedures and their risks. Written informed consent was obtained from all subjects participating in the trial.

Table 1 shows the study design and subject allocation. The starting dose was determined based on 1/10 of the projected target therapeutic dose. The estimated maximum dose was calculated to be 1/10 of the maximum dose tolerated in long-term toxicology studies in dogs. Sample size was set based on the literature [48]. In the single ascending dose part of the study, a modified Fibonacci increment strategy was applied, giving rapid escalation in the lower doses and moderate escalation in the higher doses. DQTM tablets were administered to 60 subjects (cohorts 1–8) in the following doses (dose of active ingredients in mg): 90, 270, 540, 1080, 1800, 2880, 4320 or 5760. In the multiple ascending dose part of the study, DQTM tablets were administered twice daily to 24 subjects in cohorts 9–11 for 14 consecutive days in

| Cohort | Single-dose study (once) | Multiple-dose study (twice daily for 14 days) |
|--------|--------------------------|--------------------------------------------|
|        | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| Increase,% | Starting dose | 200 | 100 | 100 | 67 | 60 | 50 | 33 | – | – | – |
| Dose | 90 | 270 | 540 | 1080 | 1800 | 2880 | 4320 | 5760 | 360 | 720 | 2160 |
| Men | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 4 | 4 | 4 |
| Women | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 4 | 4 | 4 |
| Group allocation | Active ingredients | 4 | 6 | 6 | 6 | 6 | 6 | 6 | 4 | 6 | 6 | 6 |
| Placebo | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Total | 6 | 8 | 8 | 8 | 8 | 8 | 8 | 6 | 8 | 8 | 8 |

*mg of active ingredients*
doses of 360, 720 or 2160 mg of active ingredients. The multiple-dose study was performed after the single-dose study. The study began with the lowest-dose group. The next-highest dose was not given until the safety data for the preceding dose had been reviewed.

Volunteers were instructed to abstain from taking any drugs, including over-the-counter medications, for 2 weeks before and during the study period. They were also asked to abstain from alcohol, smoking, intense physical activity, and caffeine-containing beverages during the study.

Inclusion and exclusion criteria
Healthy men and women between 18 and 45 years old who reported being non-smokers and had a body mass index between 19 and 24 were eligible for recruitment. Subjects had to be healthy based on medical history and on the following tests conducted within 2 weeks before the first drug dose: physical examination, 12-lead electrocardiography, clinical laboratory tests (hematology, blood chemistry, urinalysis), and serology (hepatitis B surface antigen, hepatitis C virus antibody, and HIV antigen/antibody).

Subjects were excluded from the study if they had any allergies or history of cardiac, pulmonary, renal, hepatic, gastrointestinal, or hematologic abnormality or any other acute or chronic disease. Subjects were also excluded if they had received any other investigational medication within 30 days of the first dose of study medication, if they were pregnant or nursing, or if they were women of childbearing potential who did not use a highly effective birth control method.

Study medication
DQTM tablet was manufactured from farmed plant material by Chongqing Fuling Pharmaceutical of the Taiji Group (Chongqing, China) in two proprietary formulations: dosage I (batch number: 10110001) contained 180 mg of salvianolic acids and saponins (active ingredients), and dosage II (batch number: 10110002) contained 90 mg of these ingredients. Plant species were identified based on the criteria of the Chinese Pharmacopoeia Commission [49]. The major active ingredients included Salvianolic acid B, Ginsenoside Rg1, Ginsenoside Rb1 and Panax notoginseng saponins R1. The final formulation was prepared using ethanol precipitation, macromolecular adsorbent and reducing pressure drying. The placebo was also manufactured by Chongqing Fuling Pharmaceutical.

Randomization and blinding
Randomization was carried out by a biostatistician using the Proc Plan Procedure in SAS 9.2 (SAS Institute, Cary, North Carolina, USA). Subjects were stratified by sex (1, 1 ratio). In cohorts 1 and 8, subjects were randomly allocated in a 2:1 ratio to receive active ingredients or placebo; in cohorts 2–7 and 9–11, the allocation ratio was 3:1 (Table 1). The randomization lists for each group were placed in sealed envelopes, and the details remained unknown to the study investigators. While researchers and subjects knew the allocated dose, they were blinded to whether the subject received drug or placebo.

Assessments
Compliance and adherence to treatment were assessed based on the ratio of actual dosage to planned dosage for each subject. Vital signs were measured at screening, pre-dose, and at 2, 4, 8 and 24 h post-dose in the single-dose study. Vital signs were measured at screening, each drug administration day (Days 1–14) and Day 15 in the multiple-dose study. Physical examination, 12-lead electrocardiography and laboratory tests (hematology, blood chemistry, blood coagulation, urinalysis) were conducted at screening and at the end of the study. Laboratory tests and 12-lead electrocardiography were also performed on Day 8 in the multiple-dose study. Haematology tests included red blood cell count, haemoglobin, white blood cell count, percentage of neutrophils, percentage of lymphocytes, and percentage of monocytes. Blood chemistry included total bilirubin, direct bilirubin, indirect bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), creatinine, blood glucose, triglyceride, cholesterol, high-density lipoprotein, low-density lipoprotein, potassium, sodium, and chloride. All laboratory tests were performed in the clinical laboratory of West China Hospital, Sichuan University, which is accredited by the College of American Pathologists.

Tolerance and safety were evaluated based on clinical symptoms, vital signs, physical examinations, electrocardiography, laboratory tests and adverse events. Adverse events were recorded on a prespecified form. We chose not to give subjects a preformulated questionnaire about adverse events in order to avoid inducement effects linked to over-reporting. Adverse events were classified as related, probably related, possibly related, possibly unrelated, or unrelated to the study medication. Adverse drug reactions were adverse events judged to be related, probably related or possibly related to the study medication.

In the multiple-dose part of the study, blood coagulation and adenosine diphosphatase (ADP)-induced platelet aggregation were tested at baseline and on Days 8 and 15 after the first dose. The following blood coagulation parameters were measured: prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), international normalized ratio (INR) and fibrinogen.
Statistical analyses
All analyses were performed using SAS 9.2 software with a significance level of 0.05. All analyses were based on an intention-to-treat approach. Inter-group differences in continuous variables were assessed for significance using a group t test or Wilcoxon rank test, while differences in categorical variables were assessed using chi-squared and Fisher’s exact tests. Subjects in the placebo group in each cohort were pooled into a single control group in the single- and multiple-dose studies. This procedure is aligned with practices in the literature [50, 51]. In the multiple-dose part of the study, repeated-measures analysis of variance was used to assess the significance of changes in variables related to platelet aggregation and coagulation.

Results
A total of 122 healthy volunteers were screened, and 84 underwent random allocation and completed the study (Fig. 1). All drugs were administered by trained researchers in the Phase I Trial Unit, and subject compliance with treatment was 100%. All enrolled subjects were included in tolerability assessment. The single-dose part of the study contained 60 subjects; the multiple-dose part, 24 subjects (Table 2). Subjects receiving active ingredients or placebo did not differ significantly in age or body mass index.

After drug administration, none of the cohorts showed clinically or statistically significant variations in vital signs, hematology, blood chemistry, urinalysis or electrocardiography (Additional file 1: Table S1). Treatment and placebo groups differed significantly in changes from baseline in the following cases: cohort 1 for TT; cohort 3 for PT and INR; cohort 4 for red blood cell count, hemoglobin, platelet count, total bilirubin, PT, and INR; and cohort 7 for creatinine. However, none of these differences was clinically significant.

Table 3 summarizes adverse events in the study. Six of 72 (8.3%) subjects who received active ingredients experienced adverse events and adverse drug reactions. In the single-dose part of the study, four subjects who received active ingredients experienced adverse events, which were classified as related to the study drug: one subject in cohort 4 and two in cohort 8 experienced one or two additional stools per day over baseline. Stool analyses were normal, and fecal occult blood tests were negative. One subject in cohort 4 experienced mildly elevated ALT and AST values, which self-resolved. No
### Table 2 Characteristics of subjects in each cohort

| Parameter                  | Study       | Cohort | Group receiving active ingredients | Group receiving placebo | Z*  | P*  |
|----------------------------|-------------|--------|-----------------------------------|-------------------------|------|-----|
| Age (year)                 | Single-dose | 1      | 29.00 (9.59)                      | 24.00 (7.07)            | −0.23| 0.83|
|                            |             | 2      | 21.83 (1.47)                      | 22.00 (0.00)            | 0.17 | 0.87|
|                            |             | 3      | 23.83 (1.17)                      | 22.00 (1.41)            | −0.69| 0.51|
|                            |             | 4      | 24.00 (2.53)                      | 24.50 (3.54)            | 0.00 | 1.00|
|                            |             | 5      | 23.83 (2.04)                      | 23.00 (1.41)            | −0.34| 0.75|
|                            |             | 6      | 23.83 (0.98)                      | 23.00 (1.41)            | 0.00 | 1.00|
|                            |             | 7      | 25.67 (1.97)                      | 25.00 (0.00)            | −0.17| 0.87|
|                            |             | 8      | 24.75 (0.96)                      | 24.00 (1.41)            | −0.48| 0.65|
|                            | Multiple-dose| 9      | 24.00 (2.28)                      | 24.00 (1.41)            | 0.17 | 0.87|
|                            |             | 10     | 23.83 (2.40)                      | 23.50 (3.54)            | 0.00 | 1.00|
|                            |             | 11     | 22.50 (1.64)                      | 22.50 (0.71)            | 1.70 | 0.13|
| Height (cm)                | Single-dose | 1      | 167.00 (8.08)                     | 168.50 (12.02)          | 0.00 | 1.00|
|                            |             | 2      | 165.17 (9.85)                     | 162.50 (10.61)          | −0.34| 0.74|
|                            |             | 3      | 169.17 (7.08)                     | 169.00 (5.56)           | 0.00 | 1.00|
|                            |             | 4      | 167.67 (6.98)                     | 166.00 (8.45)           | 0.00 | 1.00|
|                            |             | 5      | 168.17 (4.71)                     | 166.00 (8.49)           | −0.17| 0.87|
|                            |             | 6      | 165.17 (12.06)                    | 164.50 (7.78)           | 0.17 | 0.87|
|                            |             | 7      | 166.33 (6.95)                     | 167.00 (14.14)          | 0.00 | 1.00|
|                            |             | 8      | 166.50 (6.95)                     | 160.00 (0.00)           | −0.70| 0.48|
|                            | Multiple-dose| 9      | 163.00 (9.12)                     | 164.00 (5.66)           | 0.34 | 0.74|
|                            |             | 10     | 169.50 (7.45)                     | 172.50 (0.71)           | 0.50 | 0.62|
|                            |             | 11     | 167.00 (7.32)                     | 159.00 (12.73)          | −0.67| 0.50|
| Weight (kg)                | Single-dose | 1      | 57.75 (9.22)                      | 62.00 (14.14)           | 0.46 | 0.64|
|                            |             | 2      | 56.33 (10.54)                     | 58.00 (4.24)            | 0.50 | 0.62|
|                            |             | 3      | 58.83 (10.63)                     | 64.00 (12.73)           | 0.67 | 0.50|
|                            |             | 4      | 60.83 (8.80)                      | 58.50 (9.19)            | −0.17| 0.86|
|                            |             | 5      | 59.83 (4.31)                      | 54.50 (7.78)            | −1.07| 0.29|
|                            |             | 6      | 58.17 (9.06)                      | 56.50 (10.61)           | −0.51| 0.61|
|                            |             | 7      | 59.00 (7.32)                      | 56.50 (13.44)           | −0.17| 0.87|
|                            |             | 8      | 59.50 (6.66)                      | 49.50 (0.71)            | −1.41| 0.16|
|                            | Multiple-dose| 9      | 58.17 (12.95)                     | 57.50 (3.54)            | 0.00 | 1.00|
|                            |             | 10     | 62.33 (9.35)                      | 62.50 (3.54)            | 0.17 | 0.87|
|                            |             | 11     | 60.42 (8.18)                      | 54.75 (13.79)           | −0.50| 0.62|
| Body mass index (kg/m²)    | Single-dose | 1      | 20.59 (1.23)                      | 21.60 (1.83)            | 1.16 | 0.25|
|                            |             | 2      | 20.53 (1.63)                      | 22.00 (1.26)            | 0.83 | 0.40|
|                            |             | 3      | 20.41 (2.03)                      | 22.28 (0.35)            | 1.17 | 0.24|
|                            |             | 4      | 21.54 (1.73)                      | 21.14 (1.17)            | −0.17| 0.87|
|                            |             | 5      | 21.14 (1.00)                      | 19.72 (0.82)            | −1.50| 0.13|
|                            |             | 6      | 21.25 (1.47)                      | 20.77 (1.96)            | −0.50| 0.62|
|                            |             | 7      | 21.30 (2.08)                      | 20.07 (1.41)            | −0.83| 0.40|
|                            |             | 8      | 21.40 (0.95)                      | 19.34 (0.28)            | −1.62| 0.11|
|                            | Multiple-dose| 9      | 21.24 (1.67)                      | 21.37 (0.16)            | 0.00 | 1.00|
|                            |             | 10     | 21.58 (1.52)                      | 21.01 (1.36)            | −0.84| 0.40|
|                            |             | 11     | 21.57 (1.39)                      | 21.43 (2.02)            | 0.00 | 1.00|

Values are mean (SD)
Wilcoxon test
adverse event was observed in the placebo group. In the multiple-dose part of the study, two subjects who received active ingredients experienced mild adverse events that were judged to be related to the study drug: one subject in cohort 11 experienced one or two additional stools per day over baseline for 3 days, and one subject in cohort 11 experienced two additional stools over baseline during 1 day of drug administration. Stool analyses were normal and fecal occult blood tests were negative. One subject in the placebo group in cohort 11 experienced cough and runny nose, which was mild and judged to be unrelated to the study drug. No intervention was taken against the adverse events, and no subject discontinued the study because of such events.

Table 4 presents repeated-measures analysis of variance in platelet aggregation in the multiple-dose part of the study. Platelet aggregation did not change significantly over time within each group, nor did it differ significantly between groups over time. Groups receiving active ingredients or placebo did not differ significantly in platelet aggregation, PT, APTT, TT, INR or fibrinogen (data not shown).

### Discussion
Like many traditional Chinese medicines, the combination of *Salvia miltiorrhiza* and *Panax notoginseng* has been used clinically for a long time, yet its formulation in the DQTM tablet appears not to have been rigorously assessed for safety and tolerability. Here we conducted such an assessment by administering single and multiple doses of DQTM tablet to 84 healthy Chinese volunteers. All volunteers who enrolled in our study completed it, and compliance with treatment was 100%. We did not observe any clinically or statistically significant changes in vital signs, hematology, blood chemistry, urinalysis or electrocardiography at any dose tested, including at a single dose of 5760 mg, which is approximately 10 times the dose routinely used in the clinic. These results suggest that DQTM is well tolerated.

Given the small sample in this phase I trial, we analyzed individual-level data. We observed that the most frequent adverse event after study drug administration was an increase in the number of daily stools. These events occurred primarily in the single-dose groups receiving intermediate and high doses, as well as in the multiple-dose group receiving the highest dose. All these events, which were classified as related to DQTM, were mild. These results suggest that DQTM may stimulate peristalsis of the gastrointestinal tract, which may be a beneficial side effect for ischemic heart disease patients with constipation. At the same time, one subject in cohort 4 who

| Parameter | Adverse event | Increase in no. daily stools | Elevated ALT and AST | Cough and runny nose |
|-----------|---------------|-----------------------------|----------------------|----------------------|
| No. cases | 5             | 1                           | 1                    | 1                    |
| Cohort (no. of cases) | 4 (1), 8 (2), 11 (2) | 4 (1)                       |                      | 11 (1)              |
| Group     | Active ingredients | Active ingredients           | Placebo              |                      |
| Severity  | Mild           | Mild                        | Mild                 |                      |
| Duration, days | 1–2            | 5                           | 16                   |                      |
| Relationship to study drug | Probably or possibly related | Probably related         | Unrelated            |                      |
| Outcome   | Recovered spontaneously | Recovered spontaneously     | Recovered spontaneously |                      |

*ALT* Alanine aminotransferase, *AST* Aspartate transaminase

---

**Table 3** Summary of adverse events

| Parameter | Adverse event | Increase in no. daily stools | Elevated ALT and AST | Cough and runny nose |
|-----------|---------------|-----------------------------|----------------------|----------------------|
| No. cases | 5             | 1                           | 1                    | 1                    |
| Cohort (no. of cases) | 4 (1), 8 (2), 11 (2) | 4 (1)                       |                      | 11 (1)              |
| Group     | Active ingredients | Active ingredients           | Placebo              |                      |
| Severity  | Mild           | Mild                        | Mild                 |                      |
| Duration, days | 1–2            | 5                           | 16                   |                      |
| Relationship to study drug | Probably or possibly related | Probably related         | Unrelated            |                      |
| Outcome   | Recovered spontaneously | Recovered spontaneously     | Recovered spontaneously |                      |

**Table 4** Platelet aggregation (%) at different time points

| Treatment       | Cohort | Dose, mg twice daily | Baseline       | Day 8             | Day 15            |
|-----------------|--------|----------------------|----------------|-------------------|-------------------|
| Placebo         | –      | –                    | 61.50 (24.34)  | 52.67 (23.84)     | 68.17 (13.82)     |
| Active ingredients | 9     | 360                  | 56.17 (31.56)  | 68.83 (13.24)     | 55.00 (15.19)     |
| Active ingredients | 10    | 720                  | 63.50 (14.17)  | 42.83 (13.91)     | 58.00 (17.78)     |
| Active ingredients | 11    | 2160                 | 77.00 (7.24)   | 67.00 (16.78)     | 72.83 (12.73)     |
| Repeated-measures analysis of variance | Group F | 2.83 | 0.06  | 0.97  | 0.36  |
| Time            | F      | 2.83                 | 0.06            | 0.97              | 0.36              |
| Group*Time      | F      | 1.29                 | 0.3             |                   |                   |

Values are mean (SD), unless otherwise noted

*Denote the interaction
received a single dose of 1080 mg experienced mildly elevated ALT and AST. This suggests the potential of DQTM to cause clinically important adverse drug reactions, which should be monitored in future work.

The mechanism of action of DQTM tablet is not completely clear. *Salvia miltiorrhiza* and *Panax notoginseng* exhibit various bioactivities related to processes underlying ischemic heart disease [23, 29]: they have been shown to improve lipid metabolism in an ischemic heart model in rats [52, 53], improve heart contractility in rats with myocardial infarction [54], and exert cardioprotection against ischemia/reperfusion injury in rats [55]. We focused on coagulation function and platelet aggregation in this phase I study because the two plants have been shown to inhibit platelet aggregation or affect coagulation in animal studies [17–19, 24, 25, 31, 47], patients with hypertension [16], and patients with acute coronary syndrome [22]. Preliminary pharmacodynamics analysis in the multiple-dose part of our study did not suggest an effect of DQTM on coagulation or platelet aggregation. However, we did observe a trend (*P* = 0.06) toward platelet aggregation on Day 8 in subjects receiving 720 or 2160 mg. Our failure to observe significant anti-platelet or anti-coagulation effects may reflect our small sample, especially since baseline platelet aggregation varied substantially. It may also reflect the fact that our study involved healthy individuals rather than patients.

Although we chose our sample based on the literature [48], the small size may limit the reliability of our findings. Large studies in patients are needed to explore the mechanism of DQTM tablet. Future work should aim to identify individual active ingredients in the complex mixture of the DQTM tablet. It should also analyze DQTM pharmacokinetics in detail, which is a bottleneck for many traditional Chinese medicines.

**Conclusion**

This study suggests that DQTM tablet is well tolerated at single doses of up to 5760 mg and twice-daily doses of up to 2160 mg for 14 consecutive days. The most frequent adverse event was an increase in the number of daily stools. Based on these encouraging safety results, a randomized, placebo-controlled, multi-center phase II study has been launched to evaluate the efficacy of DQTM tablet for ischemic heart disease.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s12906-019-2751-x.

Additional file 1: Table S1. Changes in hematology, blood chemistry and coagulation from baseline in treatment and placebo groups.

**Abbreviations**

ACEI: Angiotensin-converting enzyme inhibitors; ADP: Adenosine diphosphate; ALT:Alanine aminotransferase; APTT: Activated partial thromboplastin time; ARB: Angiotensin receptor blocker; AST: Aspartate transaminase; CABG: Coronary artery bypass grafting; DQTM: Dan Qi Tong Mai; INR: International normalized ratio; PCI: Percutaneous coronary intervention; PT: Prothrombin time; SAS: Statistical Analysis System; SD: Standard deviation; TT: Thrombin time

**Acknowledgements**

We sincerely thank all the subjects who volunteered for this trial.

**Disclosure**

Part of the present work was presented as an abstract at the Annual Meeting of the Society for Clinical Pharmacology and Therapeutics on March 6–9, 2013 in Indianapolis, IN, USA.

**Authors’ contributions**

PF and ZPG made substantial contributions to the conception and design of the study, as well as data acquisition, analysis and interpretation. PF, ZPG, YW, JHM and ML performed the experiments. WZ and XFL managed and analysed the data. YZ assisted in the literature review and data analysis. PF and WZ wrote the paper, which YZ and PF revised. Each author participated sufficiently in the work to take public responsibility for appropriate portions of the content. All authors read and approved the final manuscript.

**Funding**

This study was funded by the Taiji Group (Chongqing, People’s Republic of China). The funder had no role in the trial design and no influence on data collection, analysis, or reporting.

**Availability of data and materials**

Data are available from the corresponding author upon reasonable request and the approval of the data owner.

**Competing interest**

The authors declare that they have no competing interests.

**Ethics approval and consent to participate**

The study was approved by the Independent Ethics Committee of West China Hospital (2011 Clinical Trial (TCM) Review (No. 1). Written informed consent was obtained from all subjects participating in the trial.

**Consent for publication**

Not applicable.

**Author details**

1Institute of Clinical Trials, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, People’s Republic of China. 2Cheng Fei Hospital, Chengdu, Sichuan 610041, People’s Republic of China. 3Taiji Group Research Institute, Chongqing 401147, People’s Republic of China.

Received: 19 February 2019 Accepted: 11 November 2019 Published online: 27 November 2019

**References**

1. Nowbar AN, Howard JP, Finegold JA, Asaria P, Francis DP. 2014 global geographic analysis of mortality from ischaemic heart disease by country, age and income: statistics from World Health Organisation and United Nations. Int J Cardiol. 2014;174(2):293–8.
2. Barquera S, Pedroza-Tobías A, Medina C, Hernandez-Barrera L, Bibbins-Domingo K, Lozano R, et al. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Arch Med Res. 2015;46(5):328–38.
3. Chen WW, Gao RL, Liu LS, Zhu ML, Wang W, Wang YJ, et al. Representative Chinese cardiovascular disease report group. Essentials of cardiovascular disease report in China. Chin Circ J. 2018;33(1):1–8.
4. Yang GH, Wang Y, Zeng YX, Gao GF, Liang XF, Zhou MG, et al. Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet. 2013;381(9882):1987–2015.
5. Marzilli M, Merz CN, Boden WE, Bonow RO, Capozza PG, Chilian WM, et al. Obstetric coronary atherosclerosis and ischemic heart disease: an elusive link! J Am Coll Cardiol. 2012;60(1):951–6.
6. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. J Am Coll Cardiol. 2012;60:e1–e144.
7. Winnderer S, Kohn P, Alfonso F, Coller JP, Cremer J, Fakk V, et al. 2014 ESC/ACTS guidelines on myocardial revascularization. Eur Heart J. 2014;35:2541–69.
8. Maron DJ, Ting HH. In mildly symptomatic patients, should an invasive strategy with catheterization and revascularization be routinely undertaken? In mildly symptomatic patients, an invasive strategy with catheterization and revascularization should not be routinely undertaken. Circ Cardiovasc Interv. 2013;6(1):114–21.
9. Helgason CM, Bolin KM, Hoff JA, Winkelk Sr, Mangat A, Tortorice KL, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 1994;25:2331–6.
10. Münzel T, Daiber A, Gori T. Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation. 2013;132:1232–44.
11. Xu LJ, Huang GY. The chemical components and pharmacological effects of Danshen. Zhong Xi Yi Jie He Yan Jiu. 2009;15:45–8.
12. Bao J, Liu G, Cong DL, Zhang CX. Progress in study of chemical components of Sanqi. Zhong Cheng Yao. 2006;28:246–53.
13. Chinese Pharmacopoeia Commission. Pharmacopoeia of The People's Republic of China, vol. 1. Beijing: People's Medical Publishing House; 2005. p. 213–4. 2008–210 (in English).
14. Zhou L, Zuo Z, Chow MS, Sing M. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 2005;45(12):1345–59.
15. TO C. Cardiovascular effects of Danshen. Int J Cardiol. 2007;121(1):9–22.
16. Li J, Liu WX, Ma CM, Chen ZY, Li JH. Effect of compound Danshen dropping pills on platelet aggregation ratio in patients with aspirin resistance. Chin J New Drugs. 2009;18(15):1424–6.
17. Li CZ, Yang SC, Zhao FD. Experimental studies on the mechanism of inhibition upon thrombus formation by salvia miltiorrhiza bunge in vitro. Acta Acad Med Primae Shang Hai. 1979;6(3):145–9.
18. Yu WG, Xu L. Effect of acetylsalicylic acid on a platelet function. Acta Pharm Sin. 1994;29(7):412–6.
19. Li LN. Water soluble active components of Salvia miltiorrhiza and related plants. J Chin Pharm Sci. 1997;6(2):57–64.
20. Yang FG, Zhang AY, Chen ZY, Lian ZX, Liu GX, Dong GX. Effects of salvinolic acid B on cardiovascular endothelial cells and platelet activation in a rabbit model of ischemia–reperfusion. J Chin Integr Med. 2008;12(1):250–4.
21. Wang SB, Tian S, Yang F, Yang HG, Yang XY, Du GH. Cardioprotective effect of salvinolic acid a on isoproteinerol-induced myocardial infarction in rats. J Pharm. 2009;30(6):125–32.
22. Liu L, Li J, Zhang Y, Zhang SH, Ye QJ, Wen ZC, et al. Salvinolic acid B inhibits platelets as a P2Y12 antagonist and PDE inhibitor: evidence from clinic to laboratory. Thromb Res. 2014;134(4):866–76.
23. Guo JW, Deng ZJ, Fu HY, Huang YF, Yang M, Pan JQ, et al. Effects of Panax Notoginsenoside R1 on platelet aggregation and improving myocardial morphological rat with post-myocardial infarction-ventricular remodeling. Acta Sci Nat Univ Sunyatseni. 2008;42(3):140–2.
24. Lau AJ, Toh DF, Chua TK, Pang YK, Woo KO, Koh HL. Antiplatelet and anticoagulant effects of Panax notoginseng: comparison of raw and steamed Panax notoginseng with Panax ginseng and Panax quinquefolium. J Ethnopharmacol. 2002;85(3):380–6.
25. Wang MM, Xue M, Xu YG, Miao Y, Kou N, Yang L, et al. Panax notoginseng saponin is superior to aspirin in inhibiting platelet adhesion to injured endothelial cells through COX pathway in vitro. Thromb Res. 2016;141:146–52.
26. Zhou LG, Zheng GZ, Gan FY, Wang SL, Yang CX. Separation and identification of main medicinal saponin components from mass cell cultures of Panax notoginseng (Burk) F. H. Chen Acta Pharm Sin. 1991;26(1):876–80.
27. Chen Y, Sorensen U. Determination of marker constituents in radix Gynostemma and radix Notoginseng by near infrared spectroscopy. Fresenius J Anal Chem. 2003;376:491–6.
28. Wang Y, Bi KS. Fingerprint construction of Panax notoginseng. China J Chin Mater Med. 2003;28(4):316–20.
29. Chen JB, Xu JW, Jiang H, Huang CX, Tang QZ, Li J J, et al. The effect of notoginsenoside on lipid peroxide and plasminogen activator of patients with coronary diseases. Chin New Drugs. 2002;11:781–2.
30. Duan L, Xiong XJ, Hu JY, Liu YM, Wang J. Efficacy and safety of oral Panax Notoginseng saponins for unstable angina patients: a meta-analysis and systematic review. Phytomedicine. 2018. https://doi.org/10.1016/j.phymed.2018.04.044.
31. Shang Q, Xu H, Liu Z, Chen K, Liu J. Oral Panax notoginseng preparation for coronary heart disease: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med. 2013;2013:12 Article ID 940125.
32. Yuan J, Guo W, Yang B, Liu P, Wang Q, Yuan H. 116 cases of coronary atherosclerosis treated with powder composed of radix ginseng, radix notoginseng and sucumum. J Tradit Chin Med. 1997;17:14–7.
33. Li J, Wang Q. Pharmacological advancement in curing coronary heart disease of compound Danshen dripping pills. Shanshi J Tradit Chin Med. 2001;1756–7.
34. Ding N. Research advancement and clinical application of compound Danshen dripping pills. Chin Tradit Herb Drugs. 2002;33:1147–8.
35. Liu L, Lu L. Pharmacology and clinical application of Fufang Danshen tablet. Heilongjiang Med J. 2005;18:59–60.
36. Wu FH, Liu XM, Jia R. Pharmacodynamic study of Danshi capsule. China J Chin Mater Med. 2005;30(3):1869–73.
37. Wang G, Wang L, Xiong ZY, Mao B, Li TQ. Compound salvia pellet, a traditional Chinese medicine, for the treatment of chronic stable angina pectoris compared with nitrates: a meta-analysis. Med Sci Monit. 2006;12:S1–7.
38. Guo YM, Zhang G, Zha QL, Chen WN, Jiang M, Lv AP. "Compound Salvia droplet pill" for treatment of coronary heart disease: a systematic review. Acta Univ Tradit Sinens Pharmacol Shanghai. 2012;26(3):24–31.
39. Yue XQ, Xie FB, Song XY, Wu WJ, Jiang BH, Guan SH, et al. Proteomic studies on protective effects of salvinic acid, notoginsenosides and combination of salvinic acid and notoginsenosides against cardiac ischemia-reperfusion injury. J Ethnopharmacol. 2012;141:659–72.
40. Yao Y, Wu WY, Liu AH, Deng SS, BS KS, Liu X, Guo DA. Interaction of salvinolic acids and notoginsenosides in inhibition of ADP-induced platelet aggregation. Am J Chin Med. 2008;36(2):313–28.
41. Buoen C, Bjørnem OJ, Thomsen MS. How first-time-in-human studies are being performed: a survey of phase I dose-escalation trials in healthy volunteers published between 1995 and 2004. J Clin Pharmacol. 2005;45:1123–36.
42. Chinese Pharmacopoeia Commission. Pharmacopoeia of The People's Republic of China, vol. 1. Beijing: People's Medical Publishing House; 2010. p. 11–70.
43. Behrens F, Tak PP, Østergaard M, Stolov R, Wiland P, Huizinga TW, et al. MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/Ila randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis. 2015;74:1058–64.
44. Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, et al. Linealglitin, a dipeptidyl peptide-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. Clin Ther. 2010;32(6):1188–204.
45. Wang Y, et al. Danshii pill regulates lipid metabolism disorder induced by myocardial ischemia through FATP-CPTI pathway. BMC Complement Altern Med. 2015;15:28.
53. Wang Q, Li C, Zhang Q, Wang Y, Shi T, Lu L, et al. The effect of Chinese herbs and its effective components on coronary heart disease through PPARs-PGC1alpha pathway. BMC Complement Altern Med. 2016;16(1):514.

54. Deng Y, Zhang T, Teng F, Li D, Xu F, Cho K, et al. Ginsenoside Rg1 and Rb1, in combination with salvianolic acid B, play different roles in myocardial infarction in rats. J Chin Med Assoc. 2015;78(2):114–20.

55. Deng Y, Yang M, Xu F, Zhang Q, Zhao Q, Yu H, Li D, Zhang G, Lu A, Cho K, et al. Combined salvianolic acid B and ginsenoside Rg1 exerts cardioprotection against ischemia/reperfusion injury in rats. PLoS One. 2015;10:e0135435.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.